318 related articles for article (PubMed ID: 33913265)
1. The Korean Society for Neuro-Oncology (KSNO) Guideline for Adult Diffuse Midline Glioma: Version 2021.1.
Yoon HI; Wee CW; Kim YZ; Seo Y; Im JH; Dho YS; Kim KH; Hong JB; Park JS; Choi SH; Kim MS; Moon J; Hwang K; Park JE; Cho JM; Yoon WS; Kim SH; Kim YI; Kim HS; Sung KS; Song JH; Lee MH; Han MH; Lee SH; Chang JH; Lim DH; Park CK; Lee YS; Gwak HS;
Brain Tumor Res Treat; 2021 Apr; 9(1):1-8. PubMed ID: 33913265
[TBL] [Abstract][Full Text] [Related]
2. The Korean Society for Neuro-Oncology (KSNO) Guideline for WHO Grade III Cerebral Gliomas in Adults: Version 2019.01.
Kim YZ; Kim CY; Lim J; Sung KS; Lee J; Oh HJ; Kang SG; Kang SH; Kong DS; Kim SH; Kim SH; Kim SH; Kim YJ; Kim EH; Kim IA; Kim HS; Roh TH; Park JS; Park HJ; Song SW; Yang SH; Yoon WS; Yoon HI; Lee ST; Lee SW; Lee YS; Wee CW; Chang JH; Jung TY; Jung HL; Cho JH; Choi SH; Choi HS; Hong JB; Lim DH; Chung DS;
Brain Tumor Res Treat; 2019 Oct; 7(2):63-73. PubMed ID: 31686436
[TBL] [Abstract][Full Text] [Related]
3. The Korean Society for Neuro-Oncology (KSNO) Guideline for WHO Grade II Cerebral Gliomas in Adults: Version 2019.01.
Kim YZ; Kim CY; Wee CW; Roh TH; Hong JB; Oh HJ; Kang SG; Kang SH; Kong DS; Kim SH; Kim SH; Kim SH; Kim YJ; Kim EH; Kim IA; Kim HS; Park JS; Park HJ; Song SW; Sung KS; Yang SH; Yoon WS; Yoon HI; Lee J; Lee ST; Lee SW; Lee YS; Lim J; Chang JH; Jung TY; Jung HL; Cho JH; Choi SH; Choi HS; Lim DH; Chung DS;
Brain Tumor Res Treat; 2019 Oct; 7(2):74-84. PubMed ID: 31686437
[TBL] [Abstract][Full Text] [Related]
4. The Korean Society for Neuro-Oncology (KSNO) Guideline for Glioblastomas: Version 2018.01.
Kim YZ; Kim CY; Lim J; Sung KS; Lee J; Oh HJ; Kang SG; Kang SH; Kong DS; Kim SH; Kim SH; Kim SH; Kim YJ; Kim EH; Kim IA; Kim HS; Roh TH; Park JS; Park HJ; Song SW; Yang SH; Yoon WS; Yoon HI; Lee ST; Lee SW; Lee YS; Wee CW; Chang JH; Jung TY; Jung HL; Cho JH; Choi SH; Choi HS; Hong JB; Lim DH; Chung DS;
Brain Tumor Res Treat; 2019 Apr; 7(1):1-9. PubMed ID: 31062525
[TBL] [Abstract][Full Text] [Related]
5. A National Consensus Survey for Current Practice in Brain Tumor Management II: Diffuse Midline Glioma and Meningioma.
Kim SK; Yoon HI; Yoon WS; Cho JM; Moon J; Kim KH; Kim SH; Kim YI; Kim YZ; Kim HS; Dho YS; Park JS; Park JE; Seo Y; Sung KS; Song JH; Wee CW; Lee SH; Lim DH; Im JH; Chang JH; Han MH; Hong JB; Hwang K; Park CK; Lee YS; Gwak HS;
Brain Tumor Res Treat; 2020 Apr; 8(1):11-19. PubMed ID: 32390349
[TBL] [Abstract][Full Text] [Related]
6. The Korean Society for Neuro-Oncology (KSNO) Guideline for Antiepileptic Drug Usage of Brain Tumor: Version 2021.1.
Moon J; Kim MS; Kim YZ; Hwang K; Park JE; Kim KH; Cho JM; Yoon WS; Kim SH; Kim YI; Kim HS; Dho YS; Park JS; Yoon HI; Seo Y; Sung KS; Song JH; Wee CW; Lee MH; Han MH; Hong JB; Im JH; Lee SH; Chang JH; Lim DH; Park CK; Lee YS; Gwak HS;
Brain Tumor Res Treat; 2021 Apr; 9(1):9-15. PubMed ID: 33913266
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Indicators for H3K27M-Mutant Diffuse Midline Glioma: A Population-Based Retrospective Surveillance, Epidemiology, and End Results Database Analysis.
Adhikari S; Bhutada AS; Ladner L; Cuoco JA; Entwistle JJ; Marvin EA; Rogers CM
World Neurosurg; 2023 Oct; 178():e113-e121. PubMed ID: 37423332
[TBL] [Abstract][Full Text] [Related]
8. Spinal Cord Diffuse Midline Glioma, H3K27M- mutant Effectively Treated with Bevacizumab: A Report of Two Cases.
Yabuno S; Kawauchi S; Umakoshi M; Uneda A; Fujii K; Ishida J; Otani Y; Hattori Y; Tsuboi N; Kohno S; Noujima M; Toji T; Yanai H; Yasuhara T; Date I
NMC Case Rep J; 2021; 8(1):505-511. PubMed ID: 35079510
[TBL] [Abstract][Full Text] [Related]
9. Diffuse midline glioma H3K27M mutation in adult: A case report.
Bhattarai AM; Mainali G; Jha P; Karki P; Adhikari A; Pandit A; Bhattarai AM
Ann Med Surg (Lond); 2022 Apr; 76():103567. PubMed ID: 35495373
[TBL] [Abstract][Full Text] [Related]
10. Pediatric midline H3K27M-mutant tumor with disseminated leptomeningeal disease and glioneuronal features: case report and literature review.
Navarro RE; Golub D; Hill T; McQuinn MW; William C; Zagzag D; Hidalgo ET
Childs Nerv Syst; 2021 Jul; 37(7):2347-2356. PubMed ID: 32989496
[TBL] [Abstract][Full Text] [Related]
11. The Korean Society for Neuro-Oncology (KSNO) Guideline for the Management of Brain Tumor Patients During the Crisis Period: A Consensus Survey About Specific Clinical Scenarios (Version 2023.1).
Kim MS; Go SI; Wee CW; Lee MH; Kang SG; Go KO; Kwon SM; Kim W; Dho YS; Park SH; Seo Y; Song SW; Ahn S; Oh HJ; Yoon HI; Lee SW; Lee JH; Cho KR; Choi JW; Hong JB; Hwang K; Park CK; Lim DH;
Brain Tumor Res Treat; 2023 Apr; 11(2):133-139. PubMed ID: 37151155
[TBL] [Abstract][Full Text] [Related]
12. Targeted therapy with anlotinib for a H3K27M mutation diffuse midline glioma patient with PDGFR-α mutation: a case report.
Wang Q; Niu W; Pan H
Acta Neurochir (Wien); 2022 Aug; 164(8):2063-2066. PubMed ID: 34812950
[TBL] [Abstract][Full Text] [Related]
13. STAT3 is a biologically relevant therapeutic target in H3K27M-mutant diffuse midline glioma.
Zhang L; Nesvick CL; Day CA; Choi J; Lu VM; Peterson T; Power EA; Anderson JB; Hamdan FH; Decker PA; Simons R; Welby JP; Siada R; Ge J; Kaptzan T; Johnsen SA; Hinchcliffe EH; Daniels DJ
Neuro Oncol; 2022 Oct; 24(10):1700-1711. PubMed ID: 35397475
[TBL] [Abstract][Full Text] [Related]
14. Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort.
Odia Y; Hall MD; Cloughesy TF; Wen PY; Arrillaga-Romany I; Daghistani D; Mehta MP; Tarapore RS; Ramage SC; Allen JE
Neuro Oncol; 2024 May; 26(Supplement_2):S165-S172. PubMed ID: 38386699
[TBL] [Abstract][Full Text] [Related]
15. Advanced MR imaging and
Piccardo A; Tortora D; Mascelli S; Severino M; Piatelli G; Consales A; Pescetto M; Biassoni V; Schiavello E; Massollo M; Verrico A; Milanaccio C; Garrè ML; Rossi A; Morana G
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1685-1694. PubMed ID: 31030232
[TBL] [Abstract][Full Text] [Related]
16. Clinicohistoradiological and surgical outcome in diffuse midline glioma.
Kumar Suman A; Bhattacharjee S; Uppin MS; Fathima ST
Childs Nerv Syst; 2024 Jan; 40(1):65-71. PubMed ID: 37644138
[TBL] [Abstract][Full Text] [Related]
17. The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies.
Persson ML; Douglas AM; Alvaro F; Faridi P; Larsen MR; Alonso MM; Vitanza NA; Dun MD
Neuro Oncol; 2022 Sep; 24(9):1408-1422. PubMed ID: 35481923
[TBL] [Abstract][Full Text] [Related]
18. Diffuse midline glioma: review of epigenetics.
Cooney TM; Lubanszky E; Prasad R; Hawkins C; Mueller S
J Neurooncol; 2020 Oct; 150(1):27-34. PubMed ID: 32804378
[TBL] [Abstract][Full Text] [Related]
19. Current perspectives on diffuse midline glioma and a different role for the immune microenvironment compared to glioblastoma.
Pachocki CJ; Hol EM
J Neuroinflammation; 2022 Nov; 19(1):276. PubMed ID: 36403059
[TBL] [Abstract][Full Text] [Related]
20. Purine salvage promotes treatment resistance in H3K27M-mutant diffuse midline glioma.
Peterson ER; Sajjakulnukit P; Scott AJ; Heaslip C; Andren A; Wilder-Romans K; Zhou W; Palavalasa S; Korimerla N; Lin A; O'Brien A; Kothari A; Zhao Z; Zhang L; Morgan MA; Venneti S; Koschmann C; Jabado N; Lyssiotis CA; Castro MG; Wahl DR
Cancer Metab; 2024 Apr; 12(1):11. PubMed ID: 38594734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
